Declaration

I hereby declare that the thesis entitled Understanding Immune Suppression of Natural Killer cells in Head and Neck Squamous Cell Carcinoma, submitted to School of Sciences, Tezpur University, in partial fulfillment for the award of the degree of Doctor of Philosophy in Molecular Biology and Biotechnology, has been carried out by me at Department of Molecular Biology and Biotechnology, Tezpur University, Assam, India, under the supervision of Prof. Shashi Baruah. The work is original and has not been submitted in part or full in any other University or institute for any degree, diploma, associateship, fellowship or any other similar title or recognition.

Date: 28/12/2022

Place: Tezpur University, Assam, India

(Saurav Phukan)

Department of Molecular Biology and Biotechnology

School of Sciences

Tezpur University

Napaam, 784028, Assam, India



DEPARTMENT OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY TEZPUR UNIVERSITY NAPAAM, TEZPUR-784 028 ASSAM, INDIA,

S. Baruah, Ph.D.

Professor

Tel: +91-3712-267007/8/9 Ext. 5408 (O)

Fax: +91-3712-267005/6

Email: sbaruah@tezu.ernet.in

CERTIFICATE OF THE PRINCIPAL SUPERVISOR

This is to certify that the thesis entitled Understanding Immune Suppression of Natural Killer cells in Head and Neck Squamous Cell Carcinoma, submitted to School of Sciences, Tezpur University, in partial fulfillment for the award of the degree of Doctor of Philosophy in Molecular Biology and Biotechnology, is a record of research work carried out by Mr. Saurav Phukanunder my supervision and guidance.

All help received by him from various sources have beer acknowledged. No part of the thesis has been submitted elsewhere for award of any other acgree.

Date: 28.12.2022

Place: Tezpur University, Assam, India

(Shashi Baruah)

Principal Supervisor



CERTIFICATE OF EXTERNAL EXAMINER AND ODEC

This is to certify that the thesis entitled Understanding Immune Suppression of
Natural Killer cells in Head and Neck Squamous Cell Carcinoma, submitted by
Mr. Saurav Phukan to Tezpur University in the Department of Molecular Biology and
Biotechnology under the School of Sciences in partial fulfillment of the requirement
for award of the degree of Doctor of Philosophy in Molecular Biology and
Biotechnology has been examined by us on and found to
be satisfactory.
The committee recommends for the award of the degree of Doctor of Philosophy
Signature
Principal Supervisor External Examiner
Date: Date:

Acknowledgment

By the abundant grace of blessings of God and His everlasting light of guidance, I was able to accomplish this work. As I reach another cornerstone in my academic career, I wish to express my eternal feeling to those whose strong support and motivation made possible to present my research work in the form of the thesis.

First and foremost, I would want to express my sincere thanks to my supervisor **Prof. Shashi Baruah** for believing in, supporting, and encouraging my efforts as well as for stimulating my mind and providing direction during the current study.

I would like to express my sincere gratitude and profound thanks to our former and present Hon'ble Vice chancellor **Prof. Vinod Kumar Jain and Prof. Dhruba Kumar Bhattacharyya** respectively, for giving inspiration and advice and providing all the necessary facilities during the course of my research work.

I also want to express my gratitude to the members of my doctoral committee, **Dr. S.P.G. Ponnam**, **Dr. Venkata Satish Kumar Mattaparthi**, and **Dr. Munindra Narayan Baruah**,

for their guidance, advice, and support during my study. Their personal participation, prompt

assistance, and fascinating conversation greatly assist me in my study work.

I appreciate having capitalized on this great opportunity given to me at Tezpur University. The facilities at Tezpur University have allowed me to enhance my personal experience and life both academically and personally. I sincerely acknowledge and express my gratefulness to all the faculty members of department of Molecular Biology and Biotechnology, Tezpur University for their valuable suggestions, inspirations and support to carry out my research work.

I like to thank our funding agencies, Indian Council of Medical Research (ICMR), Govt. of India (Grant ID: NCD/NER/2/2016-17) and Department of Biotechnology, Government of India (Grant ID: BT/22/NE/2011) for the financial support in carrying out the research work.

I also extend my sincere appreciation to all the past and present members of Immunology and

Immunogenetics laboratory, Department of Molecular Biology and Biotechnology, Tezpur

University that I have had the pleasure to work with or alongside; Dr. Anupam Dutta, Dr.

Anusree Mahanta, Mr. Arunav Benarjee, Miss. Indrani Kalita, Dr. Akash Protim Gogoi, Dr.

Debashree Talukdar, Dr. Neelanjana Sarmah, Miss Mayuri Bora, Mr. Gurumayum Chourajit

Sharma, Miss Bhaswatee Das, Miss Sushmita Singha, Miss Dalal Hemaya and Mr. Arunav

Saikia.

I extend my special thanks to Dhruba, Pankaj, Kuldeep da, and Reba for accompanying me

and making my life enjoyable during the study. I also like to thank all past and present

research scholars of Department of Molecular Biology and Biotechnology, Tezpur

University, with whom I have spent a lot of time at Tezpur University.

The largest thank must go to my parents and all my family members without whom I would

never have got to this stage. Nothing can be matched with the moral support, blessings and

everything else that I have received from my father Mr. Sobhan Phookan and my mother

Mrs. Lila Phukan throughout my life, who showed me this beautiful world and always stand

by me during hardships and ups and down in my life. I am fortunate enough to have my sister

Miss. Priyanka Phukan with whom I have spent my childhood and have been a constant

source of inspiration for me. Their unconditional love and support during my good and bad

times help me to step forward in my journey. I express my heartiest thanks to them.

Date:

Place: Tezpur University, Assam, India

(Saurav Phukan)

viii

List of Abbreviations

ADCC Antibody-dependent cell-mediated cytotoxicity

APC Antigen presenting cell

BDCA3 Blood Dendritic Cell Antigen 3

B-associated transcript 3

BCL B-cell lymphoma

cDC Conventional/classical dendritic cell

CMP Common myeloid progenitors

CLP Common lymphoid progenitors

COX2 Cyclooxygenas-2

CCL Chemokine (C-C motif) ligand

CTL Cytotoxic T lymphocytes

CMV Cytomegalovirus

CLL Chronic lymphocytic leukemia

CTLA-4 Cytotoxic T-Lymphocyte Antigen 4

CAR Chimeric antigen receptor

DC Dendritic cells

DNAM-1 DNAX Accessory Molecule-1

DR Death receptor

DcR Decoy receptor

ER Endoplasmic reticulum

EGFR Epidermal growth factor receptor

EP Prostaglandin E2 receptor

FoxP3 Fork head box P3

GM-CSF Granulocyte macrophage colony-stimulating factor

GMP Granulocyte/macrophage progenitors

HLA Human Leucocyte Antigen
HSC Hematopoietic stem cell

HA Hemagglutinin

IFN Interferon

Ig Immunoglobulin

LPS Lipopolysaccharides

LC Langerhans cells

KIR Killer-cell immunoglobulin-like receptor

LAK Lymphokine-activated killer cell

M-CSF Macrophage colony-stimulating factor

mDC Monocyte-derived dendritic cells

MHC I, II Major histocompatibility complex class I or II

MPP Multipotent progenitors

MDP Macrophage-DC progenitors

MICA/B Major histocompatibility complex class I-related chain A/B

MCA 3'-methylcholanthrene

MDSC Myeloid-derived suppressor cells

mAB Monoclonal antibodies

NK Natural killer cells

NCR Natural cytotoxic receptor

NKG2D Natural killer group 2, member D

PGE2 Prostaglandin E2

PD Programmed cell death

PD-L1 Programmed cell death-ligand 1

TLR Toll-like receptor

TCR T cell receptor

Th T helper cell

TNF Tumor necrosis factor

TGF Transforming growth factor

HPV Human papilloma virus

CNV Copy number variation

VEGF Vascular endothelial growth factor

List of Figures

Table No.	Description	Page No.
Figure 1	Recognition of target cell by NK cells	3
Figure 2	Operation of activating and inhibiting KIRs on NK cells	5
Figure 3	Mechanism of NK cell dysfunction in Tumor microenvironment	10
Figure 4	Distribution of KIR2DL1 in world population	72
Figure 5	(A): Neighbor-Joining Dendogram of our study population with 38 world populations (B) Principal component analysis of the study population with other world populations	78
Figure 6	Frequency for KIR2DL1 alleles in the study population	79
Figure 7	A maximum likelihood phylogenetic tree of most frequent KIR2DL1 alleles. Bootstraps were calculated for 100 iterations.	80
Figure 8	A maximum likelihood phylogenetic tree of HLA-C alleles in the population. Bootstraps were calculated for 100 iterations	81
Figure 9	Representative images of chromatogram and NCBI-BLAST results for amplicons of (A) & (E) KIR2DL1*002 (B) & (F) KIR2DL1*003 (C) & (G) HLA-C*07 and (D)& (H) HLA-C*14	82-84
Figure 10	Representative images of predicted structures of KIR2DL1 alleles using ITASSER server	85
Figure 11	Distribution of KIR2DL1 alleles in HNSCC patients and Healthy controls	105
Figure 12	Distribution of HLA-C1 and HLA-C2 in HNSCC patients and Healthy controls	105

Figure 13	Comparison of KIR2DL1 copy number variation	107
	in (A) HNSCC patients (B) Healthy controls	
Figure 14	(A)Copy Number Variation of KIR2DL1 in	108
Figure 14	HPV Positive HNSCC samples (N=15)	108
	HEV FOSITIVE HINSCC samples (N=13)	
	(B)Percentage of individuals with KIR2DL1	
	CNV in HPV positive HNSCC Patients	
77	(A) G AV A AV A AV A AV AV AV AV AV AV AV AV	100
Figure 15	(A)Copy Number Variation of KIR2DS1 in HPV	108
	Positive HNSCC samples (N=15)	
	(B)Percentage of individuals with KIR2DS1	
	CNV in HPV positive HNSCC Patients	
	-	
Figure 16	(A)Copy Number Variation of KIR2DL1 in	109
	HPV Negative HNSCC samples (N=15)	
	(B)Percentage of individuals with KIR2DL1	
	CNV in HPV Negative HNSCC Patients	
	Civy mili y regunyo in (See Tunonis	
Figure 17	(A)Copy Number Variation of KIR2DS1 in HPV	109
	negative HNSCC samples (N=15)	
	(B)Percentage of individuals with KIR2DS1	
	CNV in HPV negative HNSCC Patients	
Figure 18	Expression of SHP-2 Phosphatase in HNSCC	110
1 iguic 10	patients with different KIR-HLA compound	110
	genotype (N=50)	
	genotype (11–30)	
Figure 19	Expression of pro- and anti-inflammatory	111
	cytokines in HNSCC patients relative to healthy	
	controls	
Figure 20	Expression of proliferation and differentiation	112
Tigute 20	markers and KIR2DL1 and HLA-C in HNSCC	112
	tumor tissue	
	tumor tissue	
Figure 21	(A) CD56brightCD16-CD9+, CD49a+ dNK	122
	cells nurturing in the reproductive system,	
	helping embryo implant and fetal development.	
	dNK cells produce proangiogenic factors (B)	
	CD56brightCD16-, CD9+, and CD49a+ dNK-	
	like cells, displaying protumor activities, and	
•		

	nurturing in cancer	
Figure 22	Single cell suspension culture of post operated tumor tissue by enzymatic method - Cells in RPMI and DMEM media obtained from explants method (400X) RPMI media (A), DMEM media (B) and Phase contrast image (C)	126-127
Figure 23	Single cell suspension culture of post operated tumor tissue by explant culture - Cells in RPMI and DMEM media obtained from explants method (400X) RPMI media (A), DMEM media (B) and Phase contrast image (C)	128
Figure 24	Exclusion of B-cells and NK cells from CD3+ T cells in (A) Controls (B) HNSCC Patient	129
Figure 25	Graphical representation of CD56 vs CD16 Plot in (A) Controls (B) HNSCC patient	130
Figure 26	Hypothetical model showing the effect of KIR2DL1 Copy Number Variation and HLA-C in NK Cell activation in the study population	140

List of Tables

Table No.	Description	Page No.
Table 1	HLA-C allele percentage frequency table from the study	81
Table 2	Summary of interface statistics for KIR2DL1*003-HLA-CW4, KIR2DL1*005-HLA-CW4 and KIR2DL1*004-HLA-CW4 complexes determined from PDBsum server.	87
Table 3	Reverse transcription - PCR master mix composition	99
Table 4	PCR program for cDNA synthesis from total RNA	99
Table 5	Sequences of primers	121
Table 6	SYBR Green based RT- PCR master mix composition using RT2qPCR Primer Assay	100
Table 7	SYBR Green based RT- PCR master mix composition using designed primer	101
Table 8	PCR program for SYBR Green based RT- PCR assay	101
Table 9	Demographic and clinical characteristics of patients	102-103
Table 10	Comparison of HLA-C ligands between HNSCC patients and healthy controls	106
Table 11	Study of NK cells maturation status in HNSCC patients' blood and tumor tissue.	129